Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,861 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recombinant interferon beta in chronic myelogenous leukemia.
Aulitzky WE, Després D, Rudolf G, Aman J, Peschel C, Huber C. Aulitzky WE, et al. Among authors: huber c. Semin Hematol. 1993 Jul;30(3 Suppl 3):14-6. Semin Hematol. 1993. PMID: 7694372 No abstract available.
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Nickenig C, Dreyling M, Hoster E, Ludwig WD, Dörken B, Freund M, Huber C, Ganser A, Trümper L, Forstpointner R, Unterhalt M, Hiddemann W. Nickenig C, et al. Among authors: huber c. Ann Oncol. 2007 Jan;18(1):136-142. doi: 10.1093/annonc/mdl348. Epub 2006 Oct 27. Ann Oncol. 2007. PMID: 17071931 Free article. Clinical Trial.
Biotherapy of chronic myelogenous leukemia.
Aulitzky WE, Peschel C, Schneller F, Huber C. Aulitzky WE, et al. Among authors: huber c. Ann Hematol. 1995 Mar;70(3):113-20. doi: 10.1007/BF01682030. Ann Hematol. 1995. PMID: 7718640 Review.
[Interferon-alpha in therapy of malignant hemoblastoses].
Schuler M, Aulitzky WE, Schneller F, Peschel C, Huber C. Schuler M, et al. Among authors: huber c. Internist (Berl). 1995 Dec;36(12):1133-8. Internist (Berl). 1995. PMID: 8567218 Review. German. No abstract available.
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.
Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Sill H, Lang A, Falk M, Duba C, Utermann G, Kühr T, Aulitzky W, Huber C. Thaler J, et al. Among authors: huber c, huber h. Ann Hematol. 1996 Jun;72(6):349-55. doi: 10.1007/s002770050185. Ann Hematol. 1996. PMID: 8767103 Clinical Trial.
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
Ganser A, Heil G, Kolbe K, Maschmeyer G, Fischer JT, Bergmann L, Mitrou PS, Heit W, Heimpel H, Huber C, et al. Ganser A, et al. Among authors: huber c. Ann Hematol. 1993 Mar;66(3):123-5. doi: 10.1007/BF01697620. Ann Hematol. 1993. PMID: 7682447 Clinical Trial.
1,861 results